{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:15Z","timestamp":1791828855764,"version":"4.3.4"},"reference-count":191,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,7,30]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Informing an international task force updating the consensus statement on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) selectively targeting interleukin-6 (IL-6) pathway in the context of immune-mediated inflammatory diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature research of all publications on IL-6 axis inhibition with bDMARDs published between January 2012 and December 2020 was performed using MEDLINE, EMBASE and Cochrane CENTRAL databases. Efficacy and safety outcomes were assessed in clinical trials including their long-term extensions and observational studies. Meeting abstracts from ACR, EULAR conferences and results on clinicaltrials.gov were taken into consideration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>187 articles fulfilled the inclusion criteria. Evidence for positive effect of IL-6 inhibition was available in various inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still\u2019s disease, cytokine release syndrome due to chimeric antigen receptor T cell therapy and systemic sclerosis-associated interstitial lung disease. Newcomers like satralizumab and anti-IL-6 ligand antibody siltuximab have expanded therapeutic approaches for Castleman\u2019s disease and neuromyelitis optica, respectively. IL-6 inhibition did not provide therapeutic benefits in psoriatic arthritis, ankylosing spondylitis and certain connective tissue diseases. In COVID-19, tocilizumab (TCZ) has proven to be therapeutic in advanced disease. Safety outcomes did not differ from other bDMARDs, except higher risks of diverticulitis and lower gastrointestinal perforations. Inconsistent results were observed in several studies investigating the risk for infections when comparing TCZ to TNF-inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-6 inhibition is effective for treatment of several inflammatory diseases with a safety profile that is widely comparable to other bDMARDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002359","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T11:27:09Z","timestamp":1662636429000},"page":"e002359","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00977106","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03263715","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02908217","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03600818","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02309359","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02287922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00977106","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02437890","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02043548","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-3390","authenticated-orcid":false,"given":"Kastriot","family":"Kastrati","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Charite University Hospital Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Chwala","sequence":"additional","affiliation":[{"name":"University Library, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[{"name":"Rheumatology, Medical University of Graz, Graz, Austria"},{"name":"Rheumatology, Hospital of Bruneck, Bruneck, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Hopital Cochin, Rheumatology, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-0385","authenticated-orcid":false,"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[{"name":"UO Pediatria II\u2014Reumatologia, Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"Glasgow Cardiovascular Research Center, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja A","family":"Stamm","sequence":"additional","affiliation":[{"name":"Section for Outcomes Research, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical University of Vienna Department of Medicine III, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"Desir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Rheumatology, LUMC, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J H","family":"Voshaar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Department of Research & Innovation, Sint Maartenskliniek, Ubbergen, The Netherlands"},{"name":"Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Schools of Medicine and Public Health, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"2025090312573972000_8.2.e002359.1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312573972000_8.2.e002359.2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295"},{"key":"2025090312573972000_8.2.e002359.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202470"},{"key":"2025090312573972000_8.2.e002359.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202469"},{"key":"2025090312573972000_8.2.e002359.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.026"},{"key":"2025090312573972000_8.2.e002359.6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of Clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203559"},{"key":"2025090312573972000_8.2.e002359.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204963"},{"key":"2025090312573972000_8.2.e002359.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209668"},{"key":"2025090312573972000_8.2.e002359.10","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with Sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"2025090312573972000_8.2.e002359.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405"},{"key":"2025090312573972000_8.2.e002359.13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3904\/kjim.2017.159","article-title":"Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis","volume":"34","author":"Baek","year":"2019","journal-title":"Korean J Intern Med"},{"key":"2025090312573972000_8.2.e002359.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148700"},{"key":"2025090312573972000_8.2.e002359.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22384"},{"key":"2025090312573972000_8.2.e002359.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207628"},{"key":"2025090312573972000_8.2.e002359.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30363-4"},{"key":"2025090312573972000_8.2.e002359.18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/kex358","article-title":"Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial","volume":"57","author":"Edwards","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.40493","article-title":"Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial","volume":"70","author":"Kremer","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.20","first-page":"437","article-title":"Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study","volume":"37","author":"Pablos","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312573972000_8.2.e002359.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205752"},{"key":"2025090312573972000_8.2.e002359.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213416"},{"key":"2025090312573972000_8.2.e002359.23","unstructured":"Kedra J , Dieud\u00e9 P , Marotte H . Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission. American College of rheumatology conference: annual meeting, USA, Atlanta, 2019:4916\u20139."},{"key":"2025090312573972000_8.2.e002359.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206350"},{"key":"2025090312573972000_8.2.e002359.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025090312573972000_8.2.e002359.26","unstructured":"Available: https:\/\/clinicaltrials.gov\/ [Accessed 20 Aug 2021]."},{"key":"2025090312573972000_8.2.e002359.27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-019-1856-4","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan","volume":"21","author":"Tanaka","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.29","doi-asserted-by":"crossref","first-page":"637.2","DOI":"10.1136\/annrheumdis-2020-eular.5465","article-title":"FRI0114\u2005EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY","volume":"79","author":"Mazurov","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312573972000_8.2.e002359.30","unstructured":"Ablynx . A dose-range finding study for ALX-0061 combination therapy in subjects with rheumatoid arthritis. available. Available: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02309359 [Accessed 09 Nov 2020]."},{"key":"2025090312573972000_8.2.e002359.31","unstructured":"Ablynx . A phase IIb study for ALX-0061 monotherapy in subjects with rheumatoid arthritis. Available: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02287922 [Accessed 09 Nov 2021]."},{"key":"2025090312573972000_8.2.e002359.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200704"},{"key":"2025090312573972000_8.2.e002359.33","first-page":"16.1","article-title":"OP0021\u2005OLOKIZUMAB, MONOCLONAL ANTIBODY AGAINST IL6, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: EFFICACY AND SAFETY RESULTS OF PHASE III CREDO-1 STUDY","volume":"79","author":"Nasonov","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312573972000_8.2.e002359.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211328"},{"key":"2025090312573972000_8.2.e002359.35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and Nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204760"},{"key":"2025090312573972000_8.2.e002359.37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025090312573972000_8.2.e002359.38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(17)30401-4","article-title":"Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study","volume":"389","author":"Aletaha","year":"2017","journal-title":"Lancet"},{"key":"2025090312573972000_8.2.e002359.39","unstructured":"Roche H-L . Torpedo study: a study on rapid effect of tocilizumab in patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (DMARDs) or anti-TNF. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00977106 [Accessed 10 Nov 2020]."},{"key":"2025090312573972000_8.2.e002359.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"2025090312573972000_8.2.e002359.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310"},{"key":"2025090312573972000_8.2.e002359.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212496"},{"key":"2025090312573972000_8.2.e002359.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.27740"},{"key":"2025090312573972000_8.2.e002359.44","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","article-title":"The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo\/active-controlled, dose-ranging study","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"2025090312573972000_8.2.e002359.46","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22110"},{"key":"2025090312573972000_8.2.e002359.47","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22598"},{"key":"2025090312573972000_8.2.e002359.48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/14397595.2017.1332507","article-title":"A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: results of the 12-week double-blind period","volume":"28","author":"Ogata","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090312573972000_8.2.e002359.49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/acr2.11188","article-title":"Subcutaneous Sarilumab in patients with rheumatoid arthritis who previously received subcutaneous Sarilumab or intravenous tocilizumab: an open-label extension of a randomized clinical trial","volume":"2","author":"Emery","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025090312573972000_8.2.e002359.50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201282"},{"key":"2025090312573972000_8.2.e002359.51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208426"},{"key":"2025090312573972000_8.2.e002359.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204761"},{"key":"2025090312573972000_8.2.e002359.53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210561"},{"key":"2025090312573972000_8.2.e002359.54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4328"},{"key":"2025090312573972000_8.2.e002359.55","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180953"},{"key":"2025090312573972000_8.2.e002359.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30636-X"},{"key":"2025090312573972000_8.2.e002359.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"2025090312573972000_8.2.e002359.58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"2025090312573972000_8.2.e002359.59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-020-02303-y","article-title":"Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials","volume":"22","author":"Malattia","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920"},{"key":"2025090312573972000_8.2.e002359.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"2025090312573972000_8.2.e002359.62","doi-asserted-by":"crossref","unstructured":"Stone J , Spotswood H , Unizony S . Time to flare in patients with new-onset versus relapsing giant cell arteritis treated with tocilizumab or placebo plus prednisone tapering: 3-year results from a randomized controlled phase 3 trial. American College of rheumatology conference: annual meeting, USA, Atlanta, 2019:3278\u201380.","DOI":"10.1136\/annrheumdis-2020-eular.1538"},{"key":"2025090312573972000_8.2.e002359.63","first-page":"4744","volume-title":"Tocilizumab in giant cell arteritis: route of administration: intravenous or subcutaneous. American College of rheumatology conference: annual meeting","volume":"71","author":"Calder\u00f3n-Goercke","year":"2019"},{"key":"2025090312573972000_8.2.e002359.64","doi-asserted-by":"crossref","first-page":"25:25","DOI":"10.1007\/s40744-020-00227-2","article-title":"A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Sirukumab in the treatment of giant cell arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090312573972000_8.2.e002359.65","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"2025090312573972000_8.2.e002359.66","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5"},{"key":"2025090312573972000_8.2.e002359.67","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"2025090312573972000_8.2.e002359.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30070-3"},{"key":"2025090312573972000_8.2.e002359.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"2025090312573972000_8.2.e002359.70","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"2025090312573972000_8.2.e002359.71","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218547"},{"key":"2025090312573972000_8.2.e002359.72","unstructured":"Ablynx . A phase II study to evaluate safety and efficacy of ALX-0061 in subjects with systemic lupus erythematosus. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437890 [Accessed 09 Nov 2021]."},{"key":"2025090312573972000_8.2.e002359.73","unstructured":"Oddis C . Tocilizumab in the treatment of refractory polymyositis and dermatomyositis (TIM). Available: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02043548 [Accessed 15 Nov 2020]."},{"key":"2025090312573972000_8.2.e002359.74","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025090312573972000_8.2.e002359.75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-546374"},{"key":"2025090312573972000_8.2.e002359.76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3470"},{"key":"2025090312573972000_8.2.e002359.77","doi-asserted-by":"crossref","first-page":"708-722","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of anti-IL-6 antibody Clazakizumab in late antibody-mediated kidney transplant rejection","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025090312573972000_8.2.e002359.78","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.854048"},{"key":"2025090312573972000_8.2.e002359.79","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2169\/internalmedicine.1099-18","article-title":"First nationwide survey of 199 patients with amyloid A amyloidosis in Japan","volume":"57","author":"Okuda","year":"2018","journal-title":"Intern Med"},{"key":"2025090312573972000_8.2.e002359.80","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIA trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.81","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208742"},{"key":"2025090312573972000_8.2.e002359.82","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-020-1051-9"},{"key":"2025090312573972000_8.2.e002359.83","first-page":"27","article-title":"Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)","volume":"27","author":"Rodriguez-Bano","year":"2020","journal-title":"Clinical Microbiology & Infection"},{"key":"2025090312573972000_8.2.e002359.84","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090312573972000_8.2.e002359.85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237693"},{"key":"2025090312573972000_8.2.e002359.86","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study","volume":"2","author":"Biran","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090312573972000_8.2.e002359.87","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025090312573972000_8.2.e002359.88","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218479"},{"key":"2025090312573972000_8.2.e002359.89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218122"},{"key":"2025090312573972000_8.2.e002359.90","unstructured":"Hermine O , Mariette X , Tharaux PL . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Internal Medicine 2020:20:20."},{"key":"2025090312573972000_8.2.e002359.91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340"},{"key":"2025090312573972000_8.2.e002359.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836"},{"key":"2025090312573972000_8.2.e002359.93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025090312573972000_8.2.e002359.94","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a Multi-Database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.95","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","article-title":"No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study","volume":"48","author":"Kim","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312573972000_8.2.e002359.96","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/acr.23737","article-title":"Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients","volume":"71","author":"Xie","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2025090312573972000_8.2.e002359.97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.98","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207870"},{"key":"2025090312573972000_8.2.e002359.99","doi-asserted-by":"crossref","first-page":"501","DOI":"10.55563\/clinexprheumatol\/hfceu3","article-title":"Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE registry","volume":"39","author":"Lukas","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312573972000_8.2.e002359.100","first-page":"310","article-title":"Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept","volume":"36","author":"Generali","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312573972000_8.2.e002359.101","first-page":"60","article-title":"Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. analysis from the record linkage on rheumatic disease study of the Italian Society for rheumatology","volume":"37","author":"Carrara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312573972000_8.2.e002359.102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2017","journal-title":"PLoS One"},{"key":"2025090312573972000_8.2.e002359.103","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214326"},{"key":"2025090312573972000_8.2.e002359.104","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","article-title":"Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study","volume":"59","author":"Gr\u00f8n","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","article-title":"Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (real) registry","volume":"17","author":"Sakai","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.107","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212825"},{"key":"2025090312573972000_8.2.e002359.108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214367"},{"key":"2025090312573972000_8.2.e002359.109","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key023"},{"key":"2025090312573972000_8.2.e002359.110","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19878004","article-title":"Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting","volume":"11","author":"Leon","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090312573972000_8.2.e002359.111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178035","article-title":"The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan","volume":"12","author":"Lim","year":"2017","journal-title":"PLoS One"},{"key":"2025090312573972000_8.2.e002359.112","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/rheumatology\/key364","article-title":"Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.113","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"2025090312573972000_8.2.e002359.114","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2025090312573972000_8.2.e002359.115","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2025090312573972000_8.2.e002359.116","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312573972000_8.2.e002359.117","doi-asserted-by":"crossref","unstructured":"Hellgren K , Di Giuseppe D , Smedby KE . Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. Rheumatology 2020.","DOI":"10.1093\/rheumatology\/keaa330"},{"key":"2025090312573972000_8.2.e002359.118","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209285"},{"key":"2025090312573972000_8.2.e002359.119","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3471"},{"key":"2025090312573972000_8.2.e002359.120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40744-016-0037-z","article-title":"Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources","volume":"3","author":"Monemi","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2025090312573972000_8.2.e002359.121","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209773"},{"key":"2025090312573972000_8.2.e002359.122","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001201","article-title":"Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study","volume":"6","author":"Barbulescu","year":"2020","journal-title":"RMD Open"},{"key":"2025090312573972000_8.2.e002359.123","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.124","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.125","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130466"},{"key":"2025090312573972000_8.2.e002359.126","doi-asserted-by":"publisher","DOI":"10.1186\/ar4358"},{"key":"2025090312573972000_8.2.e002359.127","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.843743"},{"key":"2025090312573972000_8.2.e002359.128","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204427"},{"key":"2025090312573972000_8.2.e002359.129","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-012-0595-z"},{"key":"2025090312573972000_8.2.e002359.130","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202658"},{"key":"2025090312573972000_8.2.e002359.131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/CEOR.S124381","article-title":"Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data","volume":"9","author":"Brodszky","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025090312573972000_8.2.e002359.132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The answer cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One"},{"key":"2025090312573972000_8.2.e002359.133","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l67"},{"key":"2025090312573972000_8.2.e002359.134","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the answer cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.135","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/acr.23141","article-title":"Risk of hypersensitivity to biologic agents among Medicare patients with rheumatoid arthritis","volume":"69","author":"Yun","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090312573972000_8.2.e002359.136","first-page":"134","article-title":"Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data","volume":"57","author":"Salmon","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216624","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The answer cohort study","volume":"14","author":"Ebina","year":"2019","journal-title":"PLoS One"},{"key":"2025090312573972000_8.2.e002359.138","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204345"},{"key":"2025090312573972000_8.2.e002359.139","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207872"},{"key":"2025090312573972000_8.2.e002359.140","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa027","article-title":"Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus","volume":"4","author":"Chen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2025090312573972000_8.2.e002359.141","doi-asserted-by":"crossref","unstructured":"Genovese MC , Burmester GR , Hagino O , et al . Interleukin-6 receptor blockade or TNF\u03b1 inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther 2020;22.doi:10.1186\/s13075-020-02229-5","DOI":"10.1186\/s13075-020-02229-5"},{"key":"2025090312573972000_8.2.e002359.142","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semarthrit.2017.08.001","article-title":"Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data","volume":"47","author":"Paul","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312573972000_8.2.e002359.143","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.144","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206695"},{"key":"2025090312573972000_8.2.e002359.145","doi-asserted-by":"crossref","unstructured":"Curtis JR , Sarsour K , Napalkov P , et al . Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study. Arthritis Res Ther 2015;17.doi:10.1186\/s13075-015-0835-7","DOI":"10.1186\/s13075-015-0835-7"},{"key":"2025090312573972000_8.2.e002359.146","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2019-eular.5469","article-title":"No confirmation of increased risk of idiopathic facial nerve palsy under tocilizumab","volume":"78","author":"Strangfeld","year":"2019","journal-title":"Annals of the Rheumatic Diseases Conference: annual european congress of rheumatology of the european league against rheumatism, EULAR 2019, Spain"},{"key":"2025090312573972000_8.2.e002359.147","doi-asserted-by":"crossref","unstructured":"Shin A , Dong YH , Shin S . The comparative risk of osteoporotic fractures among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a nation-wide cohort study in Korea. Annals of the Rheumatic Diseases Conference: annual european congress of rheumatology of the european league against rheumatism, EULAR 2019, Spain 2019;726.","DOI":"10.1136\/annrheumdis-2019-eular.4507"},{"key":"2025090312573972000_8.2.e002359.148","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.004"},{"key":"2025090312573972000_8.2.e002359.149","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.reprotox.2016.01.002","article-title":"Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox pharmacovigilance center","volume":"60","author":"Weber-Schoendorfer","year":"2016","journal-title":"Reprod Toxicol"},{"key":"2025090312573972000_8.2.e002359.150","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key361"},{"key":"2025090312573972000_8.2.e002359.151","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14397595.2019.1639939","article-title":"Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: a Japan phase 3 trial (HARUKA)","volume":"30","author":"Kameda","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025090312573972000_8.2.e002359.152","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","article-title":"Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up","volume":"59","author":"Fleischmann","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.153","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000731"},{"key":"2025090312573972000_8.2.e002359.154","unstructured":"Available: https:\/\/www.fda.gov\/media\/106325\/download [Accessed 10 Nov 2021]."},{"key":"2025090312573972000_8.2.e002359.155","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.156","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/kez291","article-title":"Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis","volume":"59","author":"Gr\u00f6nlund","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.157","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/rheumatology\/kez577","article-title":"Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry","volume":"59","author":"Klein","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.158","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.6091"},{"key":"2025090312573972000_8.2.e002359.159","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121389"},{"key":"2025090312573972000_8.2.e002359.160","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.854079"},{"key":"2025090312573972000_8.2.e002359.161","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13075-020-02344-3","article-title":"High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.162","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.41299","article-title":"Association of high serum Interleukin\u20106 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating Sarilumab from adalimumab or methotrexate in a post hoc analysis","volume":"72","author":"Boyapati","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.163","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.semarthrit.2017.03.024","article-title":"Tocilizumab treatment leads to improvement in disease activity regardless of CcP status in rheumatoid arthritis","volume":"47","author":"Cappelli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312573972000_8.2.e002359.164","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Sanayama","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312573972000_8.2.e002359.165","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu363"},{"key":"2025090312573972000_8.2.e002359.166","unstructured":"Humby F , Buch MH , Durez P . A randomised, open labelled clinical trial to investigate synovial mechanisms determining response-resistance to rituximab versus tocilizumab in rheumatoid arthritis patients failing TNF inhibitor therapy. American College of rheumatology conference: annual meeting, USA, Atlanta, 2019:5180\u20133."},{"key":"2025090312573972000_8.2.e002359.167","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6894374","article-title":"T-Cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy","volume":"2017","author":"Dulic","year":"2017","journal-title":"Mediators Inflamm"},{"key":"2025090312573972000_8.2.e002359.168","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-020-02163-6","article-title":"Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes","volume":"22","author":"Gabay","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.169","doi-asserted-by":"crossref","first-page":"625.2","DOI":"10.1136\/annrheumdis-2020-eular.5859","article-title":"FRI0094\u2005significant improvement of NT-PROBNP levels in rheumatoid arthritis patients treated with tocilizumab and tofacitinib","volume":"79","author":"Gerasimova","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312573972000_8.2.e002359.170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-020-02297-7","article-title":"Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study","volume":"22","author":"Toussirot","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.171","first-page":"293","article-title":"Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition","volume":"37","author":"Fioravanti","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312573972000_8.2.e002359.172","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.06.016"},{"key":"2025090312573972000_8.2.e002359.173","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jcph.1341","article-title":"FCGR2A\/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis","volume":"59","author":"Jim\u00e9nez Morales","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2025090312573972000_8.2.e002359.174","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000607"},{"key":"2025090312573972000_8.2.e002359.175","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","article-title":"Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study","volume":"35","author":"Gardette","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312573972000_8.2.e002359.176","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/kez535","article-title":"Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis","volume":"59","author":"Sch\u00e4fer","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312573972000_8.2.e002359.177","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.4164","article-title":"SAT0103\u2005the effect of bodyweight on response to intravenous or subcutaneous tocilizumab in patients with rheumatoid","volume":"79","author":"Davies","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312573972000_8.2.e002359.178","doi-asserted-by":"crossref","unstructured":"Tanaka Y , Kameda H , Saito K , et al . Effect of subcutaneous tocilizumab treatment on work\/housework status in biologic-na\u00efve rheumatoid arthritis patients using inverse probability of treatment weighting: first ACT-SC study. Arthritis Res Ther 2018;20.doi:10.1186\/s13075-018-1647-3","DOI":"10.1186\/s13075-018-1647-3"},{"key":"2025090312573972000_8.2.e002359.179","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000496"},{"key":"2025090312573972000_8.2.e002359.180","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000602"},{"key":"2025090312573972000_8.2.e002359.181","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-018-1614-z","article-title":"Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.182","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40744-020-00201-y","article-title":"Real-World persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic","volume":"7","author":"Best","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090312573972000_8.2.e002359.183","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-019-1837-7","article-title":"Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312573972000_8.2.e002359.184","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00296-020-04596-3","article-title":"Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study","volume":"40","author":"Ayaz","year":"2020","journal-title":"Rheumatol Int"},{"key":"2025090312573972000_8.2.e002359.185","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu455"},{"key":"2025090312573972000_8.2.e002359.186","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.708"},{"key":"2025090312573972000_8.2.e002359.187","unstructured":"Coronavirus (COVID-19) update: FDA Authorizes drug for treatment of COVID-19. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19 [Accessed 10 Aug 2021]."},{"key":"2025090312573972000_8.2.e002359.188","unstructured":"Roche\u2019s Actemra\/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition. Available: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-03-05b.htm [Accessed 25 Jun 2021]."},{"key":"2025090312573972000_8.2.e002359.189","unstructured":"Actemra\/RoActemra approved by the European Commission to treat patients with severe COVID-19. Available: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-12-07.htm [Accessed 30 Dec 2021]."},{"key":"2025090312573972000_8.2.e002359.190","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11330"},{"key":"2025090312573972000_8.2.e002359.191","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:58:05Z","timestamp":1756929485000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":191,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,9,8]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/rmdopen-2022-002359"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002359","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}